Actively Recruiting

Phase 3
Age: 18Years - 99Years
All Genders
NCT05236946

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Led by Tata Memorial Hospital · Updated on 2025-09-10

190

Participants Needed

1

Research Sites

316 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.

CONDITIONS

Official Title

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • ECOG performance status of 0 to 2
  • Pathologically confirmed diagnosis of non-small cell lung cancer
  • Presence of positive oncogene mutation status (EGFR or ALK)
  • Radiologically confirmed parenchymal brain metastases
  • Asymptomatic synchronous or metachronous brain metastases
  • Willingness to provide written informed consent and comply with follow-up schedule
Not Eligible

You will not qualify if you...

  • Only cerebrospinal fluid dissemination without parenchymal brain metastases
  • Brain metastases located in the brain stem
  • Prior history of radiation therapy to the brain
  • Not suitable for tyrosine kinase inhibitor therapy as determined by medical oncologist
  • Pregnant or breastfeeding females

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tata Memorial Hospital

Mumbai, Maharashtra, India, 400012

Actively Recruiting

Loading map...

Research Team

A

Anil Tibdewal, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT | DecenTrialz